[Articles] Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trials

Therapeutic assessments in Chagas disease must account probabilistically for qPCR test performance and low post-treatment parasite densities. In chronic Chagas disease in Bolivia, once-weekly benznidazole dosing for 8 weeks or daily dosing over 4 weeks have similar efficacies as the current 8 weeks daily regimen. These results suggest that the total benznidazole dose in the standard of care regimen is excessive.